BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 16388594)

  • 1. Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.
    Wang Y; Yin S; Blade K; Cooper G; Menick DR; Cabral F
    Biochemistry; 2006 Jan; 45(1):185-94. PubMed ID: 16388594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-allelic suppression of a mutation that stabilizes microtubules and confers resistance to colcemid.
    Wang Y; Veeraraghavan S; Cabral F
    Biochemistry; 2004 Jul; 43(28):8965-73. PubMed ID: 15248754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amino acid substitutions at proline 220 of beta-tubulin confer resistance to paclitaxel and colcemid.
    Yin S; Cabral F; Veeraraghavan S
    Mol Cancer Ther; 2007 Oct; 6(10):2798-806. PubMed ID: 17938271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel.
    Hari M; Yang H; Zeng C; Canizales M; Cabral F
    Cell Motil Cytoskeleton; 2003 Sep; 56(1):45-56. PubMed ID: 12905530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.
    Giannakakou P; Poy G; Zhan Z; Knutsen T; Blagosklonny MV; Fojo T
    Oncogene; 2000 Jun; 19(27):3078-85. PubMed ID: 10871860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of an epitope-tagged beta-tubulin in Chinese hamster ovary cells causes an increase in endogenous alpha-tubulin synthesis.
    Gonzalez-Garay ML; Cabral F
    Cell Motil Cytoskeleton; 1995; 31(4):259-72. PubMed ID: 7553913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance.
    Gonzalez-Garay ML; Chang L; Blade K; Menick DR; Cabral F
    J Biol Chem; 1999 Aug; 274(34):23875-82. PubMed ID: 10446152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular dynamics simulation and free energy landscape methods in probing L215H, L217R and L225M βI-tubulin mutations causing paclitaxel resistance in cancer cells.
    Tripathi S; Srivastava G; Sharma A
    Biochem Biophys Res Commun; 2016 Aug; 476(4):273-279. PubMed ID: 27233604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
    Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
    J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine.
    Hari M; Wang Y; Veeraraghavan S; Cabral F
    Mol Cancer Ther; 2003 Jul; 2(7):597-605. PubMed ID: 12883031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells.
    Ranganathan S; McCauley RA; Dexter DW; Hudes GR
    Br J Cancer; 2001 Sep; 85(5):735-40. PubMed ID: 11531260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laulimalide and paclitaxel: a comparison of their effects on tubulin assembly and their synergistic action when present simultaneously.
    Gapud EJ; Bai R; Ghosh AK; Hamel E
    Mol Pharmacol; 2004 Jul; 66(1):113-21. PubMed ID: 15213302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
    Kowalski RJ; Giannakakou P; Gunasekera SP; Longley RE; Day BW; Hamel E
    Mol Pharmacol; 1997 Oct; 52(4):613-22. PubMed ID: 9380024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
    Poruchynsky MS; Kim JH; Nogales E; Annable T; Loganzo F; Greenberger LM; Sackett DL; Fojo T
    Biochemistry; 2004 Nov; 43(44):13944-54. PubMed ID: 15518543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
    Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T
    Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heightened sensitivity to paclitaxel in Class IVa beta-tubulin-transfected cells is lost as expression increases.
    Yang H; Cabral F
    J Biol Chem; 2007 Sep; 282(37):27058-27066. PubMed ID: 17627938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest.
    Kamath K; Jordan MA
    Cancer Res; 2003 Sep; 63(18):6026-31. PubMed ID: 14522931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural organic compounds that affect to microtubule functions.
    Iwasaki S
    Yakugaku Zasshi; 1998 Apr; 118(4):112-26. PubMed ID: 9564789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel resistance in cells with reduced beta-tubulin.
    Wang Y; Cabral F
    Biochim Biophys Acta; 2005 Jun; 1744(2):245-55. PubMed ID: 15950754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human mutations that confer paclitaxel resistance.
    Yin S; Bhattacharya R; Cabral F
    Mol Cancer Ther; 2010 Feb; 9(2):327-35. PubMed ID: 20103599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.